In this episode, Jason C. Foster welcomes Carl Schoellhammer, Principal & Advanced Therapies Practice Lead at DeciBio, to discuss the importance of considering viability alongside safety and efficacy in cell and gene therapies (CGTs). Schoellhammer highlights the need for scalable and decentralized manufacturing approaches to ensure the commercial viability of these advanced therapies, as well as the challenges of maintaining consistent quality in personalized medicines, and the role of enabling technologies in addressing these hurdles. Learn more about Carl: https://www.linkedin.com/in/carl-schoellhammer/

In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Anshul Mangal, President at Project Farma, to discuss the hurdles to scalable CGT development, the importance of early strategic planning, and the role of digitalization in improving efficiency and reducing costs. Together they also highlight the potential of distributed manufacturing and the evolution of regulatory standards. Anshul Mangal is a biotech entrepreneur and executive, leading Project Farma and Precision for Medicine's Manufacturing Solutions. He has pioneered the industrialization of early cell and gene therapies. Anshul also serves on the boards of the Alliance for Regenerative Medicines, Alliance for mRNA Medicines, and IQHQ, driving advancements in next-generation medicines. Learn more about Anshul Mangal: https://www.linkedin.com/in/amangal/

On this episode of the Ori Spotlight Podcast, we're joined by Daniel Gibson Director of Cell and Gene Therapy Services at Anthony Nolan. Anthony Nolan is a charity on a mission to improve the lives of people with blood cancer and blood disorders, by connecting patients and stem cell donors, funding research into cell therapies, and supporting patients along their transplant journey. Together, Jason and Daniel discuss the barriers limiting widespread patient access to cell therapies, why we need to adapt manufacturing processes, and how regulation can ensure scaleable development. Read more about Anthony Nolan’s work: https://www.anthonynolan.org/

On this episode of the Ori Spotlight podcast, we're joined by Dr Elizabeth Woo, Vice President of Cell and Gene Therapy at ThermoFisher. With 20+ years of experience at ThermoFisher, Betty has contributed to the growth of the company's revenue from $4B to $40B through various technical, commercial and leadership roles. Throughout this episode, Betty provides her insights into how the cell and gene therapy sector is evolving and offers valuable advice for young professionals in the industry. To strengthen and advance the industry, it is crucial to welcome diverse and exceptional skillsets and talents. Betty stresses the importance of fostering diverse and inclusive work environments and takes pride in being part of an organisation where more than 40% of leadership roles are held by women. We’re very excited to see industry leaders like ThermoFisher leverage their immense pool of resources and assets to accelerate therapy development and improve access to life-saving innovative therapies for patients worldwide. A fascinating discussion that provides valuable insights for all, from young professionals entering the industry to experienced leaders in the biotech space. Learn more about Betty: https://www.linkedin.com/in/elizabeth-woo-ph-d/

On this episode of the Ori Spotlight podcast, we're joined by John Lee, Senior Vice President and Head of Cell Therapy at the Center for Breakthrough Medicines. With 20+ years of experience in cancer cell biology at Janssen and GSK, spanning small and large molecules and cell-based therapeutics, John unpicks some of the biggest challenges facing the cell and gene therapy industry. One hot topic within the industry is the “buy versus build” approach to manufacturing. As developers invest more money in building out their own capacity, John and Jason C Foster explore whether early-stage or even larger pharmaceutical companies should build, maintain, and manufacture at a huge cost. Located in the heart of “Cellicon Valley,” CBM boasts the world’s largest single-site advanced therapies facility. With everything on a single site, CBM aims to eliminate traditional logistical development and manufacturing bottlenecks, providing cell and gene development companies with a “home forever”. Learn more about John: https://www.linkedin.com/in/john-lee-27b44b4/

--

⁠Watch this episode on our Youtube channel

We’re back with the Ori Spotlight Podcast, where we’ll be hosting conversations with experts and advocates from across the cell and gene therapy sector, and exploring the latest challenges and opportunities within the industry. In this episode, we talk to Amy Kappen, founder of the Best Day Ever Foundation. Amy founded the Foundation after her daughter Sophia passed away after battling with acute lymphoblastic leukemia (ALL) in 2017. For Amy and her family, CAR-T was “a modern day miracle” that allowed them to spend more time with their daughter. There is no set timeline to grieving the loss of a child – for Amy and her family, accessing the right resources to support them during this period was challenging. In memory of Sophia, the now Foundation supports a community of families grieving the loss of a child, providing services and resources with the goal to help families regain joyful moments in their lives. Patients and their families are the reason we do the work we do. Amy was so generous in the retelling of her story and Jason C Foster was honored to sit down and talk to her. Don't miss this episode. Best Day Ever Foundation is hosting its annual ‘Shine the Night’ event on April 8th. Find out more here: https://www.bestdayeverfoundation.us/events/

--

Watch this episode on our Youtube channel

On episode 25 of the Ori Spotlight Podcast, Jason C. Foster is joined by Philip Vanek, CTO at Gamma Biosciences as they explore how the industry is evolving in a digitally connected world.   

Gamma Biosciences is a life sciences innovator focused on bioprocessing tools and technologies for the development and production of advanced therapies, including vaccines, biologics and cell and gene therapies.   

Philip is an entrepreneurial and strategic international business leader. Prior to Gamma Biosciences, he directed strategy and portfolio growth at GE Healthcare’s Cell and Gene Therapy business unit. He has also held leadership positions in a number of life sciences companies including Life Technologies, Becton Dickinson, and Lonza, and is currently a Board Member of CCRM in Toronto Canada and the ARM Foundation.  

Philip joined Jason to discuss the role of digital within the cell and gene therapy industry, overcoming manufacturing challenges to meet the demand for therapies, and how industry partnerships and collaboration can increase the momentum of progress.   

Learn more about Philip Vanek: https://www.linkedin.com/in/vanekphil/

In episode 24 of the Ori Spotlight Podcast, Jason C. Foster is joined by Matthew Durdy, CEO of CGT Catapult as they discuss the progression of the cell and gene therapy industry. 

CGT Catapult is an independent center of excellence that aims to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialization. CGT Catapult works with partners in academia and industry to ensure advanced therapies can be developed for use in health services throughout the world. 

In this episode, the demand for talent within the industry and how this is evolving as the industry progresses, as well as, the efficiency and economics of advanced therapies were just a few topics Jason and Matthew discussed. They also explored the areas within the industry where the need for innovation is most acute. 

Learn more about Matthew Durdy: https://www.linkedin.com/in/matthew-durdy/

In episode 23 of the Ori Spotlight Podcast, Jason C. Foster is joined by Jonathan Hay, Partner at Delin Ventures and Ori board member.

Delin Ventures is a venture capital firm that invests in breakthrough technologies and life science businesses that can have a positive impact on human lives. 

Having supported Ori in their $100M Series B round, Jason joined Jonathan to discuss how Ori’s mission resonated with Jonathan as an investor, key challenges in the development and deployment of advanced therapies at scale and the importance of having a multi-site parallel approach to clinical trials.  

Learn more about Jonathan Hay: https://www.linkedin.com/in/jonathan-hay-2046046/ 

In episode 22 of the Ori Spotlight Podcast, Jason C. Foster is joined by Elliot Menschik Chief Digital Officer at Resilience, and Kevin Gordon Chief Digital Officer at Ori. 

Founded in 2020, Resilience is a manufacturing and technology company building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the medicines of today and tomorrow can be made quickly, safely, and at scale.  Elliot began his career as a physician and engineer before moving into the healthtech industry, where he founded, built and invested in a number of healthtech startups. Prior to Resilience, Elliot worked at Amazon Web Services where he led the company’s work supporting startups, scaleups and investors in highly-specialized industries. He is now responsible for all things digital across Resilience, including software development, data, applications and infrastructure and security.  

Jason, Elliot and Kevin sat down together to delve into the opportunities for efficiencies within cell and gene therapy development, the future of manufacturing and digital-first automation, and to answer the pivotal question of what does good look like in cell and gene therapy?  

Learn more about Elliot Menschik: https://www.linkedin.com/in/menschik/

In episode 21, Ori CEO Jason C. Foster had the honour of being joined by two families, both of whom are strong advocates for increasing the accessibility of CAR-T therapy: Emily, Kari and Tom Whitehead from the Emily Whitehead Foundation, and Lucy and Lewis Jones, parents of Opie Jones.

Aged 5, Emily Whitehead was diagnosed with acute lymphoblastic leukemia (ALL). After relapsing twice following conventional treatment, Emily was enrolled on a Phase I clinical trial for CAR-T therapy at the Children’s Hospital of Philadelphia where she was the pediatric patient in the world to receive CAR T-cell therapy. We’re delighted to say that Emily celebrated 10 years cancer-free this summer!

At the tender age of just 5-months old, Opie was diagnosed with infant ALL. Following unsuccessful steroid treatment, and a bone marrow transplant, Opie successfully received CAR-T cell therapy at Great Ormond Street Hospital for Children NHS Foundation Trust. He is now a happy and healthy child, celebrating 1-year cancer-free this year!

Jason sat down with both families to discuss their own experiences of CAR-T therapy – exploring the differences between the UK and US healthcare systems and how current challenges limit the accessibility of CAR-T for patients. They also shared their insights into the awareness of CAR-T amongst the healthcare community and how this is rapidly changing with increased advocacy for advanced therapies.

Connect with Kari and Tom Whitehead, and the Emily Whitehead Foundation | Connect with Lucy and Lewis Jones

In episode 20 of the Ori Spotlight Podcast, Jason C. Foster is joined by Jason Bock, CEO at CTMC (a joint venture between Resilience and MD Anderson Cancer Center) as they discuss bringing advanced therapies to patients at scale. Jason has also recently joined Ori as a member of our SAB - we’re honored to have Jason’s expertise and insights support us in achieving our mission.

Jason Bock has substantial experience in biopharmaceutical development, where he has previously held senior positions at Teva Pharmaceuticals and MD Anderson. He now leads CTMC (Cell Therapy Manufacturing Center) - a joint venture between Resilience and MD Anderson Cancer Center, that was created to better enable innovation from academia and biotech, and accelerate the impact of cell therapy for patients.

Together, they both share their insights into the digitalization of CGT manufacturing, how we can overcome challenges within the CGT industry and how we can support the industrialization of novel advanced therapies.

Learn more about Jason Bock

In this episode, Omkar Kawalekar of Deloitte's NextGenTherapies practice joins Ori CEO Jason C. Foster, to explore the significance of technology and strategic collaborations in overcoming manufacturing challenges and developing advanced therapies at scale. Their conversation covers key industry hurdles like supply chain optimization and the strategic planning necessary for bringing innovative treatments to market – offering insights into how the industry can achieve commercial viability and widespread patient access to CGTs. Learn more about Omkar: https://www.linkedin.com/in/omkar-kawalekar-7406887/

For episode 19 of the Ori Spotlight Podcast, Jason C. Foster is joined by Isabelle Rivière, Director of Cell Therapy and Cell Engineering Laboratory at the Memorial Sloan-Kettering Cancer Center (MSKCC), one of the world’s leading cancer centers. Isabelle has also recently joined Ori as our newest SAB member – we’re honored to have her supporting us in achieving our mission. 

To this episode, Isabelle brings insights she has gathered from 25 years of experience within the cell and gene therapy industry. Isabelle is also a co-founder of Juno Therapeutics, a board member of the American Society of Gene and Cell Therapy (ASGCT), and past board member of the Alliance for Regenerative Medicine (ARM).

Together, Jason and Isabelle explore the most significant barriers to treating patients at scale, how automated systems - to improve monitoring, recording and tracking could help make therapies more affordable, and the importance of industry partnerships to accelerate the development of therapies and implementation of new technologies.  

Learn more about Isabelle Rivière

For episode 18 of the Ori Spotlight Podcast, Jason C. Foster is joined by Ori’s very own Chief Technology Officer, Stuart Milne. 

Stuart has extensive experience in the CGT sector, having held leadership positions across R&D, startups and scale-ups – including leading a multidisciplinary CGT R&D team from start-up (Asymptote, 2012) through to acquisition (GE Healthcare, 2017) and divestiture (Cytiva, 2020), and launching IOT-enabled products in CGT.  

Together, Jason and Stuart discuss how the industry is overcoming current manufacturing challenges, the need to build in quality throughout the development and manufacturing process, and how Ori is preparing now to be able to meet the future demands of customers, the supply chain and regulators.  

Learn more about Stuart Milne: LinkedIn

For Episode 17 of the Ori Spotlight Podcast, Jason C. Foster is joined by Mike Paglia, COO of ElevateBio, a centralized R&D and manufacturing company developing its own innovative cell and gene therapies.

Mike has 20 years of experience in biotechnology, working across the industry from therapeutic antibody manufacturing to drug development. Together, Jason and Mike discuss how ElevateBio supports the cell and gene therapy industry, the long-term benefits of digital manufacturing processes, and the importance of removing the cost barrier to CGT.

Learn more about Mike Paglia: LinkedIn

For episode 16 of the Ori Spotlight Podcast, Jason C. Foster is joined by Germfree CEO, Kevin Kyle and VP of Regulatory and Business Development, Carol Houts.

Germfree specializes in the manufacture of mobile and modular cleanrooms, laboratory equipment, cGMP facilities and biosafety labs to deliver solutions across the life science spectrum.

Together they sat down to explore how Germfree supported the industry through COVID-19 - adapting with innovation within decentralized manufacturing of cell therapy, and taking an ecosystem approach to address supply chain challenges.

Learn more about Kevin Kyle: https://www.linkedin.com/in/kevin-kyle-1b9b39/ | Carol Houts: https://www.linkedin.com/in/carol-houts-46a628a/

For episode 15 of Ori Spotlight, Jason C. Foster is joined by Jo Anne Valentino, Chief Operating Officer at Minaris Regenerative Medicine as she shares her insights into cell and gene therapy development.  

Jo Anne has extensive experience in pharmaceutical manufacturing, having previously held senior positions at Merck and Novartis. Minaris Regenerative Medicine is a CDMO dedicated to the production of CGT products, offering high-quality clinical and commercial manufacturing services, developmental solutions and technologies.  

Together, Jason and Jo Anne discuss how digital transformation can support scalability within CGT manufacturing, what can be learned from pharmaceutical supply chains, and the challenges faced within the CDMO industry.

Learn more about Jo Anne: https://www.linkedin.com/in/jo-anne-valentino/

In episode 14 of the Ori Spotlight Podcast, Jason C. Foster is joined by John Connolly, Chief Scientific Officer at the Parker Institute for Cancer Immunotherapy, who explained why and how the industry needs to increase the accessibility of CGT for patients.

The Parker Institute is a research institute on a mission – to break down infrastructure barriers that have slowed progress in the development of immunotherapies. Their infrastructure builds collaboration between researchers, non-profits and industry organizations to bring treatments to patients faster.

John sat down with Jason to discuss the value of academia and industry collaborations, the importance of flexibility and scalability in CGT manufacturing, and how as an industry we should measure the success of CGT.


Learn more about John Connolly: https://www.linkedin.com/in/john-connolly-205b337/

In episode 13 of the Ori Spotlight Podcast Jason C. Foster sits down with Mike Nicholson (President and Chief Operating Officer) and Matt Haines (Vice President of Manufacturing Operations) at Inceptor Bio, as they share their insights into the cell and gene therapy space.

Inceptor Bio is on a mission to cure difficult to treat cancers using next-generation cell therapy platforms. Their unique partnership model, with university oncology research programs, leverages their manufacturing resources and expert cell and gene therapy skills, to advance therapeutics into the clinic.

Mike and Matt catch up with Jason to discuss the opportunities and challenges of CGT manufacturing, bringing CGT to patients at scale and what they envision for the future of CGT.

Learn more about:

Mike Nicholson - LinkedIn | Matt Haines - LinkedIn

In Episode 12 of the Ori Spotlight Podcast, Jason C. Foster sits down with Northpond Ventures, investor in both Ori’s Series A and Series B funding. We caught up with Directors Adam Wieschhaus and Shaan Gandhi, as they share their insights into the cell and gene therapy space. 

Northpond Ventures is a $2.15 billion venture capitalist firm focused on life science, medicine, and technology; with 60 investments to date since its inception. Adam and Shaan lead their San Francisco and Boston offices respectively. 

Adam and Shaan sit down with Jason to discuss why bringing scalable cell and gene therapies to market is vital, the impact these therapies have on patients, and what excites them most about the investments made within the CGT space.

Learn more about:

• Adam Wieschhaus | https://www.linkedin.com/in/adamwieschhaus/
• Shaan Gandhi | https://www.linkedin.com/in/shaangandhi/

In episode 11 of the Ori Spotlight Podcast we sit down with Paul Meister, Partner at Novalis LifeSciences - lead investor of Ori Biotech’s series B round - as he shares his perspectives on the potential for CGT.
Paul has extensive experience across the pharmaceutical, biotech and life science fields, having orchestrated the merger of Thermo Electron and Fisher Scientific before becoming chair of Thermo Fisher and, later, chair and CEO of Syneos Health. In this episode, he catches up with Jason C. Foster following the closure of Ori’s $101 million series B round, to explain why he decided to join us on our mission to enable widespread patient access to CGTs and what excites him most about our partnership.

In episode 10 of the Ori Spotlight Podcast we sit down with Farlan Veraitch, Co-Founder and Chief Scientific Officer at Ori Biotech. 

Farlan is an internationally recognized expert in CGT-manufacturing, with 15 years’ experience as a leading academic at University College London, pioneering innovative technologies in CGT bioprocessing. At Ori, he leads the research and development of Ori's revolutionary manufacturing technology platforms.

In the podcast, Farlan joins Jason C. Foster to share his co-founder story and explains Ori's unique approach, borne out of a desire to dramatically bring down the cost of CGTs and enable widespread patient access of these life-changing therapies.

Learn more about Farlan | https://www.linkedin.com/in/farlan-veraitch-a677112/

In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Joe DePinto, head of Cell and Gene Advanced Therapies at McKesson, to discuss challenges and innovations in cell and gene therapy manufacturing and supply chains. Together they also highlight the importance of collaborative partnerships and digital innovations to enhance access and streamline processes within the CGT sector. Joe DePinto is a strategic and operational leader at McKesson, focusing on establishing the company as a market leader in cell, gene, and advanced therapies. With an extensive background in biotech and pharmaceuticals, Joe has helped companies pioneer advanced solutions in speciality healthcare. Learn more about Joe DePinto: https://www.linkedin.com/in/joe-depinto-4a5b7b11/details/experience/

On episode nine of the Ori Spotlight Podcast we sat down with Qasim Rafiq, Associate Professor of Cell and Gene Therapy Bioprocessing at University College London, and Thomas Heathman, Ori's Vice President of Commercial Operations.

Qasim leads the world first MSc in Manufacturing and Commercialization of Stem Cell and Gene Therapies, and was named as one of the top 20 influential and inspirational individuals in Advanced Medicine for 2020 by The Medicine Maker. 

Together, we explore one of the most significant factors affecting the high costs of CGT: the industry's ongoing talent shortage. They discuss how the problem should be addressed, bringing together academic institutions with CGT organizations to identify the evolving expertise required, not just across scientific and clinical research teams but also in digital and technology disciplines.

Learn more about Dr. Qasim Rafiq| https://www.linkedin.com/in/qrafiq/?originalSubdomain=uk

On Ori Spotlight episode eight we sat down with Robert Preti, strategic advisor at Ori. 

Robert has an illustrious background in cell and gene therapy leading innovation as Chief Strategy Officer for Minaris as well as leading the Alliance for Regenerative Medicine (ARM) for several years as chairman. 

Joining Ori Biotech's CEO Jason C. Foster, the pair discuss where cell therapy all began, its explosion into the biopharma industry scene and why there is still a lot of work today to make sure that as many patients as possible can benefit from its life-changing possibilities.

Learn more about Robert Preti | https://www.linkedin.com/in/robert-preti-41586217/

On episode seven of the Ori Spotlight Podcast we sat down with Dr. Annalisa Jenkins, Strategic Advisor for Ori and advisor to the FDA, to discuss the changes she's seen in CGT pricing and market access models over the years. 

As board chairman for many private and public companies, Annalisa recounts how it all started and how she sees the industry evolving. She's passionate about the idea that we need to continue to embrace innovation to drive down prices while still having successful companies that can meet the needs of both their patients and shareholders.

Learn more about Dr. Annalisa Jenkins| 

Dennis Powers, Vice President of Business Development & Sales Engineering at G-CON Manufacturing joins Jason C. Foster for the new episode of the Ori Spotlight Podcast.  

Dennis explains how manufacturing powerhouse G-CON is injecting innovation right into the heart of cell and gene therapy with their prefabricated cleanrooms called PODs. 

Drawing on his wealth of experience in life sciences and biotech, Dennis also shares his predictions for the manufacturing industry from his unique vantage point.

Learn more about Dennis Powers | 

Learn more about Ori Biotech | www.oribiotech.com

Rahul Singhvi, Co-Founder and CEO at Resilience joins Jason C. Foster for the new episode of the Ori Spotlight Podcast.  With extensive experience leading vaccine technologies and biotherapeutics at Merck and Takeda, Rahul co-founded Resilience in order to create the next generation of life science manufacturing, to meet the urgent need at what is an inflection point for the biotechnology industry.

Learn more about Resilience | www.resilience.com

Learn more about Ori Biotech | www.oribiotech.com

Deanna M. Petersen, Chief Business Officer at AVROBIO joins Jason C. Foster on the new episode of Ori Spotlight. 

Having led mergers and acquisitions for with some of the biggest names in biotech including Shire's $4.2 billion acquisition of ViroPharma, Deanna is unquestionably a powerhouse leader in the space. 

Now, as the 4th employee at AVROBIO, she talks about how she built a pipeline of personalized gene therapies and some of the challenges she faced. The biggest? Chemistry, Manufacturing and Controls (CMCs).

Learn more about Deanna M. Petersen | www.linkedin.com/in/dmpetersen

Learn more about Ori Biotech | www.oribiotech.com 

For episode three of Ori Spotlight, Bruce Levine, PhD., Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania Perelman School of Medicine and current President of International Society for Cell and Gene Therapy (ISCT) joins our host Jason C. Foster. 

Professor Levine pioneered the very first FDA approved CAR-T therapy Kymriah®and is a driving force across the cell and gene therapy industry, holding numerous positions at some of the most progressive CGT institutions in the world. 

In this episode he shares his perspectives on the industry shift that is needed to enable widespread access to these life-saving treatments and the responsibility of all stakeholders to make it happen.

Learn more about Ori Biotech: www.oribiotech.com | 
Learn more about Professor Bruce Levine | 

In this episode of Ori Spotlight, Jason C. Foster is joined by Tom and Emily Whitehead, along with Vincent Carrano, Director of Development and Engagement at the Emily Whitehead Foundation.

The Emily Whitehead Foundation is on a mission to make promising research and therapies, including CAR T-cell therapy, as well other immunotherapies more accessible to all patients.

Together we discuss Emily’s journey as the first child to take part in a T-cell trial, as well as the access challenges for patients in need of innovative cell and gene therapies.

Order The Whitehead Family's new book | ‘Praying for Emily’

Connect with Ori Biotech | www.oribiotech.com/connect 

Learn more about the Emily Whitehead Foundation | www.emilywhiteheadfoundation.org

On this week’s episode of Ori Spotlight, Jason C. Foster is joined by Anthony Davies, Founder and CEO of Dark Horse Consulting. 

Anthony has spent more than 20 years sharing his leadership experience in product, process and manufacturing development to cell and gene therapy (CGT) companies in need. 

We discuss some of the most significant barriers to innovation and scale in CGT and how they impact patients.

Learn more about Ori Biotech: www.oribiotech.com | info@oribiotech.com

Learn more about Dark Horse Consulting: https://darkhorseconsultinggroup.com

In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Matthew Hewitt, Vice President and Technical Officer of Cell and Gene Therapy and Biologics at Charles River Laboratories, to discuss why industry collaboration is needed to experience the true impact of advanced therapies and develop them at a commercial scale. Together they also highlight the role of technology in closing, automating and scaling manufacturing processes. Matthew has over 10 years of experience in the CGT sector, contributing to the advancement of CGTs across research and commercialization. As a member of our Strategic Advisory Board we're grateful for Matthew's insights as we work towards enabling widespread patient access to CGTs. Learn more about Matthew Hewitt: https://www.linkedin.com/in/matthewmhewitt/

In this episode of the Ori Spotlight Podcast, host Jason C. Foster is joined by Jeff Holder and Adam Siebert from LEK Consulting, who offer an in-depth exploration of the evolving cell and gene therapy (CGT) industry. LEK Consulting, a global leader in strategic advisory, aims to address the critical challenges of scalability and commercial viability within the CGT sector. Jeff and Adam, with their extensive background in life sciences consulting, share their insights on the importance of early investment in manufacturing processes to ensure that groundbreaking therapies can be delivered to patients efficiently and on a large scale. Together they explore the intricacies of CGT production, the significance of early-stage manufacturing considerations, and their vision for making advanced therapies more accessible to those in need. Learn more about: Jeff Holder - https://www.linkedin.com/in/jeff-holder-ph-d-7a391087 Adam Siebert - https://www.linkedin.com/in/adam-siebert-8772b327/

In this episode of Ori Spotlight Podcast, we welcome Jim Faulkner, PhD, Independent Consultant at JDB BioConsulting and former SVP of Product Delivery at Autolus. Jim brings a wealth of experience from his remarkable career in biopharmaceutical development and his journey in the industry is marked by significant contributions, particularly in pioneering cell therapy at GSK. The episode offers a deep dive into the evolving challenges in CGT manufacturing – centering on the critical challenges of scalability and commercial viability in CGTs – and sheds light on the unique demands and opportunities in the sector. Learn more about Jim: https://www.linkedin.com/in/drjimfaulkner/

In this episode of the Ori Spotlight Podcast, we're joined by Sanjay Srivastava, Managing Director of Accenture's Cell and Gene Therapy Practice. With his extensive background in consulting and a deep understanding of the biotechnology sector, Sanjay offers unique insights into the rapidly evolving world of cell and gene therapies. Sanjay and Jason C. Foster delve into the critical challenges facing the industry, particularly focusing on the scalability and efficiency of manufacturing processes. They discuss how these challenges impact the commercial viability of advanced therapies and the necessity of adapting our current healthcare systems to better accommodate innovative treatments. Learn more about Sanjay here: https://www.linkedin.com/in/nitreniumions/

We’re joined by Tim Hunt, CEO of Alliance for Regenerative Medicine (ARM). As an international advocacy organization, ARM is a global voice within the cell and gene therapy sector. They champion the benefits of engineered cell therapies and genetic medicines for patients, healthcare systems, and society as well as facilitating influential exchanges on policies and practices, and advances in narrative with data and analysis. In this episode, Tim and Jason C. Foster discuss why it is important to put the patient first and where we should be focusing our attention to reduce the cost of goods and improve the accessibility of cell and gene therapies. Tim also offers his advice for people and companies working in the CGT space. Learn more about Tim: https://www.linkedin.com/in/timhunt100/

We’re joined by Vered Caplan, CEO of Orgenesis, as she shares her insights into the cell and gene therapy sector. With a background in engineering and business, Vered found her passion in the cell and gene therapy industry. She founded Orgenesis with a mission to bring innovative therapies to patients, by leveraging cutting-edge science to create a more efficient, scalable, and affordable pathway to patients. In this episode, Vered discusses: 🧬 The need for greater adoption of technology to overcome manufacturing challenges of advanced therapies 🧬 Why digital is the key to tailoring manufacturing processes to the individual needs of patients 🧬 How industry partnerships support the scalability of therapy products Learn more about Vered: https://www.linkedin.com/in/vered-caplan-4366928/

In this episode of the Ori Spotlight Podcast, Jason Foster is joined by Michael Krajewski, Director at Stand Back and an expert in engineering and scaling operations. Michael, with his background in aeronautics, brings a unique perspective on the Theory of Constraints and its role in CGT manufacturing processes. Michael and Jason dive into the complex dynamics of bottlenecks and discuss how understanding constraints can pave the way for growth – without compromising efficiency. Together, they explore how manufacturing lessons from other industries can address the limitations faced by cell therapy today, and what it takes to streamline complex, regulated processes. Learn more about Michael: https://www.linkedin.com/in/michael-krajewski/

In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Boro Dropulić, CEO of Vector Biomed and Executive Director at Caring Cross.

Boro shares his vision of how decentralized manufacturing, low-cost vector production, and open-source workflows can make cell and gene therapies more accessible worldwide. They also discuss the role of digital technologies, partnerships, and innovative processes in overcoming industry bottlenecks, driving down costs, and expanding this access.

Learn more about Boro on LinkedIn

In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Amritha Jaishankar, Executive Director of the Cell and Gene Therapy Center at IQVIA, to discuss how data integration and decentralized manufacturing are reshaping access to advanced therapies. Amritha shares her insights on how to overcome systemic challenges in cell and gene therapy, including data silos, workforce gaps, and manufacturing inefficiencies. Together, they explore the transformative potential of community sites, digital platforms and collaborative partnerships in driving scalability, improving affordability of CGTs, and expanding their access worldwide. Learn more: https://www.linkedin.com/in/amrithajaishankar/

In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes back Aaron Vernon, Chief Manufacturing Officer at Quell Therapeutics, for the second part of the discussion on building robust and scalable cell therapy manufacturing systems. Together, they explore how applying principles like the Theory of Constraints, designing smarter facility layouts, and implementing digital systems can reduce bottlenecks and improve throughput.

Aaron brings over 20 years of experience leading manufacturing, engineering and supply chain operations across biologics and cell therapy. We’re grateful for his insights as the industry works to deliver more consistent, cost-effective therapies to patients at scale.

Learn more: https://www.linkedin.com/in/aaronvernon/

In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Aaron Vernon, Chief Manufacturing Officer at Quell Therapeutics, for a two-part discussion on building robust and scalable cell therapy manufacturing systems. Together they explore how applying principles like the Theory of Constraints, designing smarter facility layouts, and implementing digital systems can reduce bottlenecks and improve throughput.

Aaron brings over 20 years of experience leading manufacturing, engineering and supply chain operations across biologics and cell therapy. We’re grateful for his insights as the industry works to deliver more consistent, cost-effective therapies to patients at scale.

Learn more: https://www.linkedin.com/in/aaronvernon/

In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Dr. Julie Allickson, Chief Technology Officer for Mayo Clinic's Center for Regenerative Biotherapeutics. With over 30 years pioneering regenerative medicine - from early bone marrow transplant programs to today's cutting-edge cell and gene therapies - Julie shares her journey and insights on translating innovative therapies from discovery to clinical impact.

Together, they explore how academic medical centers are evolving to bridge the gap between research and commercialization through integrated manufacturing capabilities, multi-site clinical trials, and strategic partnerships. Julie discusses Mayo Clinic's approach to managing 30+ clinical trials across three sites, the critical role of automation and AI in reducing costs and improving scalability, and why thinking about commercial viability early in development is essential widespread patient access.

Learn more: https://www.linkedin.com/in/julie-g-allickson-phd-76129062/

In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Henrik Andersen, former SVP and Head of Cell Therapy Technology Development at Bristol Myers Squibb, to explore how early planning, automation, and economic discipline can help scale the impact of cell therapies.

Henrik draws on his experience in both biologics and cell therapy to discuss how platform thinking, target product profiles, and cost-of-goods modelling can be applied earlier in development. Together, they reflect on the pitfalls of rushing to clinic without a viable manufacturing strategy, the shift in investor expectations, and why adapting lessons from biologics could help CGT companies avoid costly detours on the path to commercial success.

Connect with Henrik

In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Arsalan Arif, founder of Endpoints News, for a wide-ranging conversation on the business of biotech. From his early days bootstrapping a media company to Endpoints’ recent partnership with the Financial Times, Arsalan shares his journey and reflections on what it takes to build trust in an evolving industry.

Together, they unpack today’s cell and gene therapy landscape, where clinical success alone isn’t enough. Arsalan offers his perspective on investor sentiment, why scaling remains the biggest challenge in CGT, and how economic models, not efficacy, will shape the next chapter of growth.

Learn more about Arsalan: https://www.linkedin.com/in/arsalanarif/

In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Lavakumar (Kumar) Karyampudi, Senior Director of Cell Therapies at Moffitt Cancer Center, to discuss how academic institutions are evolving to meet the demands of early-phase CGT trials.

Kumar shares how Moffitt is building flexible, end-to-end infrastructure that supports the full development cycle – from translational research to GMP manufacturing. Together, they explore how tighter integration between scientists, clinicians, and operational teams can accelerate first-in-human trials, why academic centres play a crucial role in advancing CGTs, and how the right partnerships can extend institutional capabilities.

Connect with Kumar: https://www.linkedin.com/in/lavakumar-karyampudi/

In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Warner Biddle, CEO of Kyverna Therapeutics, to explore how autologous CAR-T therapies can be delivered safely, efficiently, and at scale in autoimmune disease.

Warner shares Kyverna’s approach to designing a commercially viable treatment model — one that prioritizes outpatient care, streamlined manufacturing, and real-world practicality. They discuss what it means to bring complex therapies into community settings, how Kyverna is tailoring its rollout strategy by indication, and why the future of CAR-T in autoimmune disease depends as much on delivery as it does on data.

Connect with Warner: https://www.linkedin.com/in/warnerbiddle/

In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Jonathan Gluck, an award-winning journalist and author of An Exercise in Uncertainty, for a deeply personal conversation about illness, identity, and the evolving promise of cell therapy.

Jonathan shares his 20-year journey with multiple myeloma, from the early days of treatment to receiving CAR-T therapy, and reflects on what it means to live – and write – through chronic uncertainty. Together, they explore the patient experience behind clinical progress, and the human stories that often get lost between endpoints and approvals.